University of Liverpool researchers, working with F2G Limited (Eccles, Manchester), have developed a new antifungal drug to help in the treatment of life threatening invasive fungal infections such as invasiveĀ aspergillosis.
Invasive fungal infections are common and often lethal. Despite optimal medical care mortality is 20-30% at six weeks and dramatically rises to 80-100% for drug resistant infection.
These infections occur most commonly in the context of leukemia and bone marrow transplantation and often in young patients with otherwise curable disease.
Orotomides
The researchers, led by Professor William Hope from the University’s Antimicrobial Pharmacodynamics and Therapeutics (APT) Group, have characterised the biochemical and physiologic effects (pharmacodynamics) of F901318, which is the lead compound of the new class of drugs termed the ‘orotomides’.
The ‘orotomides’, discovered by F2G Limited, have a novel mechanism of action which is the specific biochemical interaction through which a drug substance produces its pharmacological effect.
This is the first new class of antifungal agent to be discovered in the last three decades.
The study, which was supported by a research grant by F2G, has been published inĀ mBio.
Clinical studies
APT’s work provides the underpinning evidence for efficacy and dosage justification for the very first patients receiving the new drug. Such information is required by regulatory agencies such as the European Medicines Agency and the Food and Drug Administration before clinical studies can proceed.
Professor Hope, said: “Antifungal resistance represents a major global clinical challenge. This study provides the necessary information to enable F901318 to be developed for clinical use.”
Learn more:Ā Researchers help develop new antifungal drug
The Latest on:Ā Antifungal drug
[google_news title=”” keyword=”antifungal drug” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Cidara stock rallies amid $240M private placement, drug updateon April 24, 2024 at 1:45 pm
Shares of Cidara Therapeutics (NASDAQ:CDTX) rallied 25% in post-market trading Wednesday after the company announced it had reacquired the rights to its antiviral drug CD388 and agreed to a $240M ...
- Pharmacies raided for selling overpriced medson April 23, 2024 at 3:39 pm
Hyderabad: Some medical shops were found to be selling certain anti-fungal medicines at almost double the actual cost, the Drugs Control Administratio.
- Changes in Renal Function After Changes in Antifungal Drug Therapyon April 22, 2024 at 4:59 pm
Secondary objectives included assessing the frequency of changes in antifungal therapy due to infusion-related reactions involving amphotericin B formulations, evaluating mycological cure rates in ...
- Combination Antifungal Therapy for Invasive Fungal Infections in Children and Adultson April 20, 2024 at 5:00 pm
Currently, there are no clear-cut recommendations for efficacious antifungal combination in these ... without a major concern about drug-related side effects. [74] However, only 30 patients ...
- Pulmocide exits OPERA with phase 2 evidence of antifungal safety and efficacyon April 15, 2024 at 6:41 am
Pulmocide saw a lower rate of drug-drug interactions that lead to discontinuation of the antifungal or an immunosuppressant in the opelconazole arm than the control group. Opelconazole won that battle ...
- Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazoleon April 15, 2024 at 5:33 am
Inhaled opelconazole observed to be generally well tolerated in this study as prophylaxis against pulmonary aspergillosis in lung transplant ...
- Fungal Foes: Understanding the Challenges of Fungal Infections and New Treatment Optionson February 22, 2024 at 8:15 am
With the rise in incidences of fungal infections and the reduced efficacy of antifungal drugs, there is an urgent need for the development of novel antifungal agents. Explore the fascinating world of ...
- The threat of fungal infections is growing. Why is it so hard to make new drugs?on February 11, 2024 at 3:06 am
Last summer, the Food and Drug Administration denied an application for a new antifungal drug called olorofim, sending it back to the company with a request for more data. If approved, it would ...
- Antifungal News and Researchon February 8, 2024 at 3:59 pm
A new antifungal molecule, devised by tweaking the structure of prominent antifungal drug Amphotericin B, has the potential to harness the drug's power against fungal infections while doing away ...
- First Cases of Drug-Resistant Ringworm Detected in U.S.on May 17, 2023 at 4:59 pm
Scientists studying the condition suspect that the fungus may have become drug-resistant due to the misuse and overuse of topical antifungal treatments and corticosteroids (anti-inflammatory ...
viaĀ Google News and Bing News